Cardiff Oncology (CRDF) CAO reports 27,431 shares and multiple option grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Cardiff Oncology chief accounting officer files initial holdings report. The Form 3 shows Brigitte Lindsay beneficially owns 27,431 shares of Cardiff Oncology common stock directly. She also holds multiple stock option awards on common stock with expiration dates from January 2028 through March 2035 and exercise prices ranging from $1.72 to $21.6 per share. Footnotes describe vesting schedules for each option grant, with portions already vested and additional shares vesting over monthly periods of up to 36 months.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Lindsay Brigitte Ute
Role
Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Options — 1,753 shares (Direct);
Common Stock — 27,431 shares (Direct)
Footnotes (1)
- 1,198 vested on January 23, 2018. 185 vested on January 23, 2019, 2020 and 2021. 29,823 vested on June 20, 2020, 2021 and 2022. 32,064 vested on June 17, 2021, 2022 and 2023. 38,676 vested on June 10, 2022 and 3,223 vested monthly for 36 months thereafter. 32,892 vested on March 9, 2023 and 2,741 vest monthly for 36 months thereafter. 22,572 vested on March 15, 2024 and 1,881 vest monthly for 36 months thereafter. 23,760 vested on March 7, 2025 and 1,980 vest monthly for 36 months thereafter. 41,580 vest on March 11, 2026 and 3,465 vest monthly for 36 months thereafter.
FAQ
What does Cardiff Oncology (CRDF) disclose in this Form 3 filing?
Cardiff Oncology discloses the initial beneficial ownership of its Chief Accounting Officer, Brigitte Lindsay. The filing lists 27,431 common shares held directly and multiple stock option grants on common stock with detailed vesting schedules, exercise prices, and expiration dates extending out to 2035.
What stock options are reported for the Cardiff Oncology (CRDF) officer?
The Form 3 lists several stock option awards on Cardiff Oncology common stock. Each grant specifies the number of underlying shares, an exercise price between $1.72 and $21.6 per share, and expiration dates ranging from 01/23/2028 through 03/11/2035.
What do the vesting footnotes in the Cardiff Oncology (CRDF) Form 3 explain?
The footnotes describe how each option grant vests over time. They specify initial vesting tranches on particular dates and then monthly vesting amounts over 36 months, clarifying how many option shares have already vested and how many are scheduled to vest in the future.
What is the officer’s role at Cardiff Oncology (CRDF) in this Form 3?
The reporting person, Brigitte Lindsay, is identified as an officer of Cardiff Oncology with the title Chief Accounting Officer. The Form 3 indicates she is not a director and not a 10% owner, but reports her beneficial ownership as a company officer.
Does the Cardiff Oncology (CRDF) Form 3 show any stock sales or purchases?
The Form 3 functions as an initial ownership report and lists holdings rather than transactions. It reports existing common stock and option positions, with no transaction codes or per-share transaction prices indicating recent open-market purchases or sales by the officer.